Rheumatology NewsBiosimilar-to-biosimilar switches deemed safe and effective, systematic review revealsAugust 15, 2022Rheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisPediatricsLupus & Connective Tissue DiseasesAnkylosing spondylitis
Rheumatology NewsStudy suggests psoriasis and PsA are underdiagnosed in underserved groupsAugust 12, 2022Psoriatic Arthritis
Rheumatology NewsACR makes changes to adult, pediatric vaccinations guidanceAugust 9, 2022Rheumatoid ArthritisPediatricsPsoriatic ArthritisSpondyloarthropathiesAnkylosing spondylitisLupus & Connective Tissue Diseases
Rheumatology NewsUstekinumab becomes second biologic approved for PsA in kidsAugust 3, 2022Psoriatic ArthritisPediatrics
Commentary: Exercise, Mental Health, and Checkpoint Inhibitors in PsA, August 2022August 2, 2022Psoriatic Arthritis
Rheumatology NewsTopical roflumilast approved for psoriasis in adults and adolescentsAugust 1, 2022Psoriatic Arthritis
Presence of PsA increases prevalence of anxiety and depression in psoriasisJuly 31, 2022Psoriatic Arthritis
PsA: Clinical and therapeutic features associated with early vs late onset of psoriasisJuly 31, 2022Psoriatic Arthritis
Reluctance of biologic initiation in systemic-therapy-naive PsA patients receiving apremilastJuly 31, 2022Psoriatic Arthritis
PsA: Long-term retention, efficacy, and safety of secukinumab in real worldJuly 31, 2022Psoriatic Arthritis
Guselkumab leads to meaningful and consistent improvement in general health outcomes in PsAJuly 31, 2022Psoriatic Arthritis
PsA: Risankizumab improves patient-reported outcomes in phase 3 trialJuly 31, 2022Psoriatic Arthritis
PsA: Sustained improvement in patient-reported outcomes with bimekizumabJuly 31, 2022Psoriatic Arthritis
PsA: Long-term efficacy and safety of ixekizumab with or without csDMARDJuly 31, 2022Psoriatic Arthritis
